Qiagen agreed to acquire Parse Biosciences for $225 million plus up to $55 million in milestones to broaden its foothold in single‑cell sample prep and informatics. Qiagen cited Parse’s instrument‑free, scalable workflow and its footprint in thousands of labs as strategic for fast‑growing single‑cell applications. The deal accompanies Qiagen’s raised guidance and share buyback plan. Separately, Berry Genomics won China NMPA approval for the PacBio Sequel II CNDx sequencer paired with a thalassemia assay—marking a regulatory first for clinical‑grade long‑read sequencing in China. Together these moves reflect accelerating commercialisation of single‑cell and long‑read platforms in both research and clinical diagnostics.